You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雲頂新耀(01952.HK)來凱醫藥(02105.HK)分別漲12%及23% 聖諾醫藥(02257.HK)瀉24%創新低
內地醫藥生物板塊繼昨天急升3.5%後,半日收續升0.9%。 本港醫藥股仍以來凱醫藥-B(02105.HK)表現最好,股價承昨日升勢,今早曾再升34%至5.4元,現報4.97元,續升23%,成交達1,088萬股,已接近昨天全日成交量。 雲頂新耀-B(01952.HK)繼昨天考驗百天線獲支持後,今天回升高見25.25元,創逾三個月高,現報24.15元,回升15%。維亞生物(01873.HK)回升5.4%報0.59元。 藥明生物(02269.HK)、中生製藥(01177.HK)、君實(01877.HK)、聯邦制藥(03933.HK)、康希諾生物(06185.HK)、開拓藥業-B(09939.HK)及翰森製藥(03692.HK)升逾1.5%-2.5%,後者股價連升第三天,最高見14.06元,現報13.72元,續升2.8%。 獲建銀國際升目標價至152元的百濟神州(06160.HK)連升第三天,最高見107.8元,現報105.7元,續升1.3%。 然而,聖諾醫藥-B(02257.HK)高開報17.38元欠承接,掉頭低見12.6元,屢創上市新低,現報12.88元,續瀉24%。康諾亞-B(02162.HK)反覆續跌近3%報34.5元。 恆指連續第二天反覆受壓,高低見16,695/16,429,現報16,516,反覆續跌20點或0.1%,總成交額456億元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account